BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics is advancing its pivotal Phase 3 clinical trial for Bria-IMT™ combined with an immune checkpoint inhibitor in metastatic breast cancer, with 35 active sites and enrollment set to complete by mid-2025. This study aims to demonstrate the effectiveness of Bria-IMT™ in improving overall survival compared to traditional treatments, potentially leading to full approval and marketing authorization. The trial has received FDA Fast Track designation, highlighting its potential impact on breast cancer therapy.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
